Bristol-Myers Squibb (BMY) Stock Analysis 2026: 9.3x Forward PE Before April 30 Earnings

Bristol-Myers Squibb trades at $58.96 × 9.3x forward earnings, 4.2% dividend yield, Risk Score 18.2 (among the lowest on the platform). On those metrics alone, BMY looks like a textbook defensive value position before Q1 2026 results on April 30. But three layers of complexity sit beneath the headline cheapness: a 1,392% TTM EPS rebound that is almost entirely a base effect, an Eliquis patent cliff beginning in 2026 that threatens ~30% of revenue, and a debt/equity ratio of 2.45x from a decade of transformational acquisitions. This analysis untangles all three.

BMY at a Glance (April 2026)

Understanding the 1,392% EPS Rebound

EPS growth of 1,392% in a trailing twelve-month period is not a sign that Bristol-Myers Squibb suddenly became a dramatically better business. It is a base-effect recovery from an exceptionally low denominator.

In 2023–2024, BMY recorded a series of massive non-cash impairment charges and in-process research & development (IPR&D) write-offs — totaling roughly $12–15B — related to its Celgene, Karuna Therapeutics, RayzeBio, and Mirati Therapeutics acquisitions. These charges compressed GAAP EPS to near-zero or negative in the affected quarters. When those one-time charges rolled off the trailing twelve-month window in 2025, EPS "recovered" to $3.46 — not because underlying profitability surged 14x, but because the write-down drag disappeared.

Forward EPS of $6.228 reflects another near-doubling from the $3.46 TTM figure. This second leg of apparent growth is more genuine: analysts are modeling Cobenfy (schizophrenia) ramping from its 2024 approval, Camzyos (hypertrophic cardiomyopathy) scaling, and Opdivo gaining additional indications. But they are also modeling Eliquis contributing its full ~$7B in 2026 before loss of exclusivity (LOE) begins to bite.

The punchline: EPS of $3.46 TTM ? $6.228 forward is not a business gaining intrinsic momentum — it is a business with a write-down hangover normalizing, ahead of a patent cliff that will reverse the trend.

The Eliquis Cliff: BMY's Keytruda Problem

Eliquis (apixaban) is BMY's best-selling drug, co-promoted with Pfizer. It generates approximately $6–8B annually and represents roughly 15–20% of total company revenue when measured through BMY's share of the collaboration economics. US loss of exclusivity is expected to begin in 2026, with generic entry accelerating through 2027–2028.

The Eliquis cliff creates a structural revenue headwind that analyst consensus already reflects — which is why the forward EPS of $6.228 may be the peak before a multi-year compression phase, not a floor above which earnings grow.

The magnitude of the risk: if Eliquis loses 50% of its US revenue to generics within two years (a conservative estimate — branded drugs often lose 80–90% within 18 months of first generic entry), the direct revenue impact is $3–4B annually. At a 30% operating margin, that translates to roughly $0.90–1.20 of EPS headwind — compressing earnings back toward the $4–5 range even if the pipeline executes perfectly.

This is why the analyst target of $63.04 (only 7% above current price) is surprisingly modest despite a 9.26x forward PE. Analysts are discounting $63 as the risk-adjusted equilibrium — pricing Eliquis LOE into the forward multiple.

The Pipeline: Can BMY Replace Eliquis?

The case for BMY depends almost entirely on whether three newly approved and recently launched drugs can fill the Eliquis revenue gap over 2026–2028:

Cobenfy (xanomeline-trospium): Approved September 2024 for schizophrenia — the first novel mechanism approved in this indication in 35+ years. Schizophrenia is a multi-billion-dollar market. Cobenfy avoids the motor side effects of traditional antipsychotics, targeting a differentiated patient population. BMY's commercial launch is being watched closely; early prescribing data from Q1 2026 will be a key metric in the April 30 print. Peak revenue estimates range from $2B to $6B annually — a wide range reflecting genuine uncertainty about payer coverage and psychiatrist adoption curves.

Camzyos (mavacamten): Approved 2022 for obstructive hypertrophic cardiomyopathy (HCM). A cardiac myosin inhibitor targeting a rare but severe condition. Revenue has been ramping steadily; current annual run-rate is approximately $600–800M with cardiologist uptake accelerating. Not Eliquis-sized, but quality recurring revenue in a disease with no prior pharmacological standard of care.

Opdivo (nivolumab) extensions: BMY's PD-1 checkpoint inhibitor continues to gain new indications through clinical trials. While KEYTRUDA (Merck) leads in overall oncology market share, Opdivo maintains a large and growing position across bladder cancer, liver cancer, and adjuvant settings. Additional combination approvals could add incremental revenue without major new investment.

The math problem: Cobenfy (best case $4B), Camzyos ($1B by 2028), Opdivo extensions ($500M) = $5.5B peak pipeline contribution. Eliquis LOE could remove $3–4B. Net: manageable, but only at peak pipeline assumptions. Any slip in Cobenfy uptake creates a revenue and earnings trough from 2026–2028.

Valuation: Multi-Method Analysis

Why the Model Shows $108 When Analysts Say $63

The model consensus of $108.21 vs the analyst target of $63.04 is a 71% gap. This is the largest divergence to understand in the BMY analysis.

The DCF/DDM inflation ($192–$206): The three-stage DCF and DDM methods use BMY's calculated growth rate of 80% — derived from the 1,392% TTM EPS rebound. This is catastrophically misleading as a forward growth input. An 80% growth rate sustained over even three years would price BMY as a hyper-growth company; in reality, growth rate normalizes toward 5–8% once the base effect and Eliquis cliff math plays out. These methods are excluded from the final consensus but do show in the full table.

The Forward PE inflation ($137): Using forward EPS of $6.228 and applying a 22x sector median PE produces $137. But pharma sector median PE includes companies with clean patent profiles. BMY trading at 9.26x forward EPS — and analysts targeting only $63 — reflects the market already applying a 10x multiple to "peak Eliquis" EPS before the cliff. The model's 22x is sector average; the market is applying a justified 10x discount for patent risk.

The EPV ($90.80) and EV/EBIT ($82.65): These are more grounded — they look at current normalized earning power. EPV at $90.80 uses current earnings without a growth assumption; EV/EBIT at $82.65 values the operating business without leverage adjustments. These provide a reasonable mid-case.

The Justified P/B ($63.11): Almost exactly matches the analyst target. BMY's book value per share is only $9.05 — eroded by acquisition goodwill and the write-downs. The justified P/B model adjusts for ROE of 40.4% and required return — arriving at $63 per share, the same number analysts use as a price target.

The honest range: Analyst target $63–$65 (7% upside from current) is the base case. If Cobenfy executes at the high end of guidance and Eliquis LOE is orderly, mid-cycle fair value could reach $80–$90 (EPV/EV/EBIT range). The DCF and DDM numbers above $140 require growth assumptions that cannot be justified given the incoming patent cliff.

Debt Load: The Acquisition Overhang

BMY's debt/equity of 2.45x tells the story of a company that transformed through acquisition:

• Celgene (2019): $74B — brought Revlimid, Pomalyst, Abraxane
• MyoKardia (2020): $13.1B — brought Camzyos (mavacamten)
• Turning Point Therapeutics (2022): $4.1B — oncology pipeline
• Karuna Therapeutics (2024): $14B — brought Cobenfy
• RayzeBio (2024): $4.1B — radiopharmaceutical platform
• Mirati Therapeutics (2024): $5.8B — KRAS oncology

This is approximately $115B of acquisition spending over seven years. The resulting debt (net debt/share of $17.19 against a $59 stock price) is a structural drag: interest expense is roughly $1.5–2B annually, which directly reduces earnings.

The upside of the debt: these acquisitions built BMY's current pipeline. Cobenfy (Karuna), Camzyos (MyoKardia), and radiopharmaceuticals (RayzeBio) are all acquired assets now approaching or in commercial stage. The debt is not waste — it funded strategic optionality that is beginning to generate returns.

The Merton distance-to-default of 37.5 sigma confirms that despite the leverage, near-term insolvency risk is essentially zero. BMY's cash flow from Eliquis (pre-cliff) covers debt service comfortably.

Dividend Sustainability

BMY pays $2.471/share annually at a 4.2% yield. Coverage analysis:

• Forward EPS: $6.228 ? payout ratio 39.7% (comfortable)
• FCF/share: $6.291 ? FCF payout ratio 39.3% (comfortable)
• Post-Eliquis scenario at $4.50 EPS: payout ratio rises to 55% (still sustainable)
• Post-Eliquis at $3.50 EPS: payout ratio 70.6% (approaching risk threshold)

BMY has grown its dividend consistently for 15+ years. The company is unlikely to cut the dividend unless EPS falls significantly below $3.50 — which would require both Eliquis LOE and pipeline failure simultaneously. The 4.2% yield appears durable under base-case scenarios.

Financial Quality Profile

ROE of 40.4% deserves context: with book value of $9.05/share (eroded by write-downs and goodwill), a $3.46 EPS generates a mathematically high ROE. This number overstates underlying capital efficiency — it reflects leverage and accounting dynamics more than operational excellence.

Beta of 0.273 means BMY moves at roughly one-quarter the amplitude of the S&P 500. This low correlation makes it genuinely defensive in portfolio context — a characteristic that supports its position in income-oriented portfolios regardless of whether the pipeline thesis plays out.

April 30 Earnings Preview

Q1 2026 results will set the tone for the Cobenfy commercial trajectory and Eliquis decline rate. Key metrics:

• Cobenfy net revenue: Any number above $200M in the first full quarter post-launch signals robust uptake. Below $100M would disappoint analyst models.
• Eliquis revenue trend: Year-over-year growth/decline rate. The market will extrapolate the generic entry impact from this quarter's trajectory.
• Camzyos: Sustained double-digit growth quarter-over-quarter confirms cardiologist adoption.
• FY2026 EPS guidance: Guidance range midpoint relative to the $6.228 analyst consensus. Any reduction triggers an re-rating to lower PE.
• Debt paydown: Reduction in gross debt confirms financial deleveraging trajectory that investors and credit markets want to see.

The options market implies a 4.2% earnings move ($2.46 on a $58.95 stock) — moderate for a large-cap pharma, consistent with the pharmaceutical sector's volatility profile.

Risk Factors

Eliquis LOE acceleration. If generic entry is faster or more aggressive than modeled, EPS could fall to $4–4.50 by 2027–2028, compressing both earnings and multiple simultaneously.

Cobenfy commercial disappointment. Schizophrenia is notoriously difficult to commercialize — patient compliance is poor, payer restrictions are common, and psychiatry is a relationship-driven specialty. If Cobenfy misses early targets, the pipeline replacement thesis weakens significantly.

Debt service burden. $17/share of net debt at current interest rates costs approximately $1.50/share in annual interest expense. Any rise in rates or credit spread widening increases this drag.

Pipeline setbacks. BMY is running numerous Phase 2 and Phase 3 trials across oncology and immunology. A major setback in any key asset could reduce the forward EPS trajectory.

High PEG ratio. The screener's PEG of 23.16x reflects that even though forward earnings look cheap in PE terms, the underlying revenue growth is only 1.3% — the PEG penalizes for the lack of organic revenue momentum.

Tools for Analysing BMY

The DCF Calculator lets you model BMY across Eliquis scenarios — set a 0% revenue growth (Eliquis replaces Cobenfy ramp), then 5% (successful pipeline transition), then -5% (Cobenfy disappoints and Eliquis LOE bites) — to see how dramatically the intrinsic value range shifts based on patent risk assumptions.

The Dividend Yield Calculator shows BMY's 4.2% yield in context of payout ratio analysis — input forward EPS and FCF to verify coverage across the Eliquis LOE scenario range.

The P/E Ratio Calculator lets you explore BMY at different multiples on both TTM EPS ($3.46) and forward EPS ($6.228) — understanding why the market applies a ~10x multiple (analyst) vs the 22x sector median is the central valuation question.

The Equity Rank screener shows Bristol-Myers Squibb's full profile alongside all 800 large-cap stocks — Overall Score 71.0, Combined MoS +36.8%, Risk Score 18.2 (Very Low), SAVE Score 68.0, Beta 0.273 — updated weekly.

This article is for informational and educational purposes only. It does not constitute financial advice or a recommendation to purchase or sell Bristol-Myers Squibb Company (BMY) shares or any other security. All scores, margin of safety estimates, and other metrics are model-based outputs subject to estimation uncertainty. A combined margin of safety of +36.8% reflects the model consensus of $108.21 — which materially overstates equity fair value because the DCF, three-stage DCF, and DDM methods use a calculated growth rate of 80% derived from the 1,392% TTM EPS rebound; this growth rate is a base-effect artifact, not a sustainable forward trajectory. The analyst consensus target of $63.04 (+6.9% upside) is the more grounded estimate for near-to-medium-term price appreciation. Eliquis loss of exclusivity beginning in 2026 represents a material revenue risk (approximately 15–20% of company revenue) not fully reflected in trailing metrics. EPS growth of +1,392% TTM reflects normalization from a low-base write-down year, not a step-change in underlying business performance. Cobenfy commercial trajectory and pipeline execution are uncertain. Debt/equity of 2.45x increases financial sensitivity. Past financial performance does not guarantee future results. All investments involve risk, including potential loss of principal. Equity Rank is not a registered investment adviser. Always conduct your own due diligence and consult a qualified financial adviser before making investment decisions.